International Immunology Advance Access originally published online on March 28, 2006
International Immunology 2006 18(5):671-677; doi:10.1093/intimm/dxl004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
c-Fos suppresses systemic inflammatory response to endotoxin
1 Department of Microbiology and Immunology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan
2 Medical Scholars Program, Vanderbilt University School of Medicine, Nashville, TN 37232-8300, USA
3 Department of Comparative Pathophysiology, Graduate School of Agricultural and Life Sciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, 113-8657 Tokyo, Japan
Correspondence to: K. Matsuo; E-mail: matsuo{at}sc.itc.keio.ac.jp
We explored the role of the transcription factor c-Fos in lipopolysaccharide (LPS)-induced cytokine response using mice lacking c-Fos (Fos/ mice). Compared with wild-type controls, Fos/ macrophages and mice showed significantly enhanced production of tumour necrosis factor (TNF)-
, interleukin (IL)-6 and IL-12 p40, but reduced production of the anti-inflammatory cytokine IL-10. Bandshift analysis revealed that LPS-induced NF-
B binding activity to a functional site in the TNF-
promoter was significantly higher in Fos/ than in wild-type macrophages. Using telemetry, we monitored body temperature and heart rate after LPS injection and found that Fos/ mice undergo more severe hypothermia and bradycardia than wild-type mice. Such shock responses in Fos/ mice were significantly reversed by neutralizing TNF-
. These data reveal a novel in vivo role for c-Fos as an anti-inflammatory transcription factor acting through suppression of NF-
B activity.
Keywords: AP-1, body temperature, cytokines, knockout mice, NF-
B, telemetry, TNF-
Transmitting editor: R. A. Flavell
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Y. Takada, N. Ray, E. Ikeda, T. Kawaguchi, M. Kuwahara, E. F. Wagner, and K. Matsuo Fos Proteins Suppress Dextran Sulfate Sodium-Induced Colitis through Inhibition of NF-{kappa}B J. Immunol., January 15, 2010; 184(2): 1014 - 1021. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morishita, F. Saito, H. Kayama, K. Atarashi, H. Kuwata, M. Yamamoto, and K. Takeda Fra-1 negatively regulates lipopolysaccharide-mediated inflammatory responses Int. Immunol., April 1, 2009; 21(4): 457 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Peng, T. Zhang, X. Lu, and Q. Feng JNK1/c-fos inhibits cardiomyocyte TNF-{alpha} expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia Cardiovasc Res, March 1, 2009; 81(4): 733 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-i. Sano, Y. Takada, S. Goto, K. Maruyama, Y. Shindo, K. Oka, H. Matsui, and K. Matsuo Flagella Facilitate Escape of Salmonella from Oncotic Macrophages J. Bacteriol., November 15, 2007; 189(22): 8224 - 8232. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yamashita, Z. Yao, F. Li, Q. Zhang, I. R. Badell, E. M. Schwarz, S. Takeshita, E. F. Wagner, M. Noda, K. Matsuo, et al. NF-{kappa}B p50 and p52 Regulate Receptor Activator of NF-{kappa}B Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1 J. Biol. Chem., June 22, 2007; 282(25): 18245 - 18253. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Iqbal and M. Zaidi CD38 is required for priming by TNF-{alpha}: a mechanism for extracellular coordination of cell fate Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1283 - F1290. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Maruyama, G.-i. Sano, N. Ray, Y. Takada, and K. Matsuo c-Fos-Deficient Mice Are Susceptible to Salmonella enterica Serovar Typhimurium Infection Infect. Immun., March 1, 2007; 75(3): 1520 - 1523. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Maruyama, Y. Takada, N. Ray, Y. Kishimoto, J. M. Penninger, H. Yasuda, and K. Matsuo Receptor Activator of NF-{kappa}B Ligand and Osteoprotegerin Regulate Proinflammatory Cytokine Production in Mice J. Immunol., September 15, 2006; 177(6): 3799 - 3805. [Abstract] [Full Text] [PDF] |
||||






